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INTRODUCTION 
Currently tobacco use causes approximately 4.9 
million deaths per year. This figure is expected to 
rise to more than 10 million deaths per year by the 
year 2030. It is estimated that 1.9 billion people use 
tobacco products worldwide.1 Tobacco maybe 
smoked in a variety of ways such as cigarettes, 
bidis, cigar, chutta, pipe, hookah, reverse smoking 
etc. The smokeless forms of tobacco are paan 
masala, areca nut, manipuri tobacco, khaini, zarda  
etc.  Smoking is one of the primary causes of both 
morbidity and mortality worldwide. One in every 
two long term smokers die due to a smoking 
related illness. For every one death, 30 people are 
left with some serious illness. On an average, a 
smoker dies 10 years younger than a non smoker.2 
Figure 1. briefly explains how tobacco addiction 
occurs. 
 
Smoking not only affects every organ of the body, 
it has deleterious effects on the oral cavity too. 
Smokers may be affected by various non 
communicable forms of diseases such as cancers 
of the lung, oral cavity, pharynx, oesophagus, 
cardiac diseases, hypertension etc. The oral effects 
of smoking are : halitosis, tooth discolouration, 
increased bone loss within the jaw, increased risk 
of developing gum disease, increased risk of tooth 
loss, delayed healing following tooth extraction, 
periodontal treatment or oral surgery, increased  
 
 
risk of white lesions (e.g. leukoplakia), increased 
risk of developing oral cancer. Along with 
smokers, the health of non-smokers is also 
endangered since passive smokers are exposed to 
five times more carbon monoxide levels. Smoking 
may negatively impact the health of people at all 
stages of life – unborn babies, infants, children, 
adults and the elderly. 
 
The knowledge of such damaging and harmful 
health effects associated with tobacco use 
warrants an immediate need for tobacco control 
and cessation. Quitting smoking has a 
considerable impact on health and overall life 
expectancy of an individual. 
 
With the advent of various non-pharmacological 
and pharmacological interventions (of which 
counselling and nicotine replacement therapy are 
the most common)to aid in smoking cessation, 
nicotine replacement therapy can be used to assist 
smokers with their addiction. NRT improves 
cessation rates by approximately 70%.3 It is 
recommended safe to use in high risk group 
patients including pregnant and breastfeeding 
women, adolescents and smokers with 
cardiovascular disease. 
 
 
 
Use of tobacco accounts for the highest number of illnesses and deaths around the world. Even though many people are well 
acquainted with the ill effects of tobacco consumption, they get addicted to its use. This addiction owes to the nicotine dependence 
in smokers or people consuming tobacco. If allowed for adequate awareness, the counselling becomes the first line of treatment but 
very few people get convinced to quit this habit and thus agents such as nicotine replacement therapy come into play as a major 
factor in increasing the number of quit rates. The efficacy may depend on the route of NRT administration which may vary from 
nicotine gums, lozenges, sublingual tablets, inhalers etc. This review article discusses both the current use and future of NRT. 
  
 
KEYWORDS: Tobacco, Nicotine gum, Replacement therapy, Transdermal patch, Nicotine safety 
K 
Targeting Nicotine Addiction - The Possibility of a 
Healthier Future 
REVIEW ARTICLE 
 
A 
B 
S
T
R
A
C
T 
International Healthcare Research Journal 
2017;1(2):5-9. 
AISHWARYA ARORA1, AMAR ANAND2, VARSHA BHATIA3 
QR CODE 
 
5 
IHRJ Volume 1 Issue 2 2017 
What is nicotine replacement therapy? 
NRT acts as a powerful intervention aid for 
smoking cessation. It is a pharmaceutical way 
which allows consumption of nicotine without the 
use of tobacco products. The use of NRT increases 
the abstinence rates by about 50-70%.4 Any 
cigarette smoker who is motivated to quit may 
receive benefits from NRT. NRT must preferably 
be given in combination with behavioural support 
– this ensures benefits to patients who are not yet 
motivated. As opposed to consumption of tobacco 
in a smokeless or smoke form – NRT products 
contain relatively less amounts of nicotine and are 
also devoid of any other chemicals or toxins. 
  
The use of NRT also reduces the nicotine 
withdrawal symptoms (such as irritability, 
difficult concentration, disturbed sleep, increased 
appetite and weight gain etc.)5 in smokers who 
refrain from smoking since administration of 
nicotine causes stimulation of nicotine receptors 
in the ventral tegmental area of the brain and 
therefore initiates release of dopamine in the 
nucleus accumbens. The use of NRT does not 
entirely eliminate the withdrawal symptoms since 
none of the available NRT systems completely 
replace the effects produced by smoking.6 The 
NRT products rely on venous absorption and 
achieve much lower levels over a period of few 
minutes (for gums, lozenges, sublingual tablets, 
nasal sprays) and hours (for transdermal patches) 
whereas the nicotine obtained from consuming 
tobacco products produces rapid arterial nicotine 
levels.7 
 
Forms of Nicotine Replacement Therapy: 
 Nicotine gum 
 Nicotine lozenges 
 Nicotine sublingual tablet 
 Nicotine oral inhaler 
 Nicotine nasal spray 
 Nicotine transdermal patch 
 
Nicotine gum: It is the first kind of NRT made 
available to consumers. Nicotine gum is available 
in two dosages – 2mg and 4mg, without a 
prescription. The gum must be periodically 
chewed and is held in mouth for about 30 minutes 
as opposed to chewing it like an ordinary gum. The 
4 mg gum is advised for heavy smokers 
(>25cigarettes/day). The dosages are gradually 
tapered down before stopping its use entirely. The 
use of gum is recommended for 1-3 months at a 
definite interval schedule.8 Minor side effects such 
as gastrointestinal problems and hiccups may be 
noticed.9 
 
Nicotine lozenges: Patients unwilling to chew 
gums may be advised help with nicotine lozenges. 
These lozenges are also available in 2mg and 4mg 
dosages. Unlike the nicotine gums, the lozenges 
are not to be chewed – these dissolve in mouth in 
about 30 minutes. The amount of nicotine 
absorbed per lozenge is relatively higher than the 
gum.8 A 4 mg dosage is usually recommended, 
although it depends on the cigarette dependency 
of the smoker. Adverse effects with lozenges are 
insomnia, cough, headache, heartburn, hiccups.9 
Both gums and lozenges are absorbed slowly 
through the buccal mucosa and delivered into 
systemic circulation.8 
 
Nicotine sublingual tablet: This tablet must be 
held under tongue for sublingual absorption. A 
2mg tablet has the same level of nicotine as a 2 mg 
gum. Similar to the lozenge, this tablet does not 
require to be chewed.  The dosage depends on the 
number of cigarettes smoked by the patient per 
day. For those smoking <20 cigarettes/day, one 
tablet/hour is recommended. Anyone smoking 
>20 cigarettes/day is advised to take two 
tablets/hour. The patient must never exceed more 
than 40 tablets in a day. The dosages should be 
gradually tapered after a period of 12 weeks.9 
 
Nicotine oral inhaler: The device consists of a 
plastic cartridge (containing nicotine) and a 
mouthpiece. This type of NRT mimics the 
behavioural aspects of smoking and reduces the 
physiological symptoms related to withdrawal. 
Even though it is an inhaler, the nicotine is 
majorly delivered to the oral cavity and very little 
to the lungs. The rate of absorption is similar to 
that of the nicotine gum.8 
 
Nicotine nasal spray: In this, nicotine is 
delivered from a spray which is rapidly absorbed 
into the bloodstream. There is 10mg/ml of 
available nicotine in each dispenser. This kind of 
NRT mimics the rapid levels of nicotine achieved 
by smoking.10 The spray is usually available on 
prescription. A single dose means two sprays - one 
to each nostril and equals 1 mg. Recommended 
dose is 1-5 sprays/hour but no more than 40  
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sprays/day. The nasal spray may however cause 
nasal and throat  irritation, coughing, sneezing 
and watery eyes. 
 
Despite of the speed by which nicotine is delivered 
to the brain, the patient compliance with nasal 
spray is lower when compared to other forms of 
NRT.9 
 
Nicotine transdermal patch: Another accessible 
method of delivering nicotine using NRT is by 
using a transdermal patch. These deliver nicotine 
at a constant rate when applied to skin. Patches 
are available in a variety of dosages (5-22mg) 
depending on the need of smoker. It delivers 
nicotine relatively slowly when compared to other 
NRT formulations. Some patches may last 16 hours 
which is to be worn for the time period the patient 
is awake while others may last 24 hours.10 The 24 
hour patch may disturb sleep, but are effective in 
reducing the early morning cravings of nicotine.  
Compared to other forms of NRT, these patches 
offer a better compliance as it avoids the active use 
of product throughout the day.8 The patient may 
apply the patch once in the morning. However, 
transdermal patches may cause local skin 
reactions. To reduce local irritation, the site of 
application must frequently be changed.8,11 Other 
side affects are gastrointestinal problems, 
headache and dizziness.9 
 
Apart from the above mentioned types of 
NRT, recent more effective advances are: 
 
Rapid release gum: These formulations release 
nicotine in two phases – increased delivery to 
enhance relief from craving followed by reduced 
release of nicotine to avoid overdosing.8 These 
gums achieve faster and more efficient relief from 
cravings compared to the conventional nicotine 
gums. They also cause a reduced craving intensity 
for tobacco products. The differences in the 
efficacy of the nicotine gum and rapid release 
nicotine gum can be seen as early as during the 
first three minutes of administration.12 
 
High dose nicotine patch: These offer nicotine 
doses of up to or greater than 42mg and are seen 
to be more efficacious than 22mg patches. 
Although these result in higher quit rates, they 
have not yet been established in medical 
literature.8 
Combination therapy: Similar to the synergistic 
effect seen in various drug interactions, 
combining a passive nicotine delivery system 
(transdermal patch) with an active nicotine 
medication (gum, lozenge, sublingual 
tablet)improves the efficacy of NRT. The passive 
system achieves constant concentration of 
nicotine – which helps relieve cravings and 
withdrawal symptoms whereas the faster acting 
preparations offer immediate relief. Using a 
combination therapy has been seen to increase 
quit rates by 34-54% compared to using a patch 
alone.8 
 
The combination therapy of NRT and bupropion 
(a potent drug for smoking cessation) also exhibits 
superior results compared to using either agent 
alone.13 
 
Nicotine vaccine: Use of vaccines is currently 
employed to  treat various disorders – among 
these vaccines many are still under investigation. 
One of such vaccinations is for the treatment of 
nicotine dependence. The nicotine vaccine is one 
of the latest approaches which aims at eliminating 
nicotine dependence. This works on the principle 
of antigen-antibody reaction. Upon smoking a 
cigarette, nicotine quickly passes into the 
bloodstream to enter the brain within seconds, 
where it causes release of dopamine to exert its 
effects similar to those caused by tobacco 
consumption.7 
 
With introduction of nicotine  vaccines, the 
immune system is prompted to produce 
antibodies against nicotine which bind to nicotine 
and thus prevent it from entering the brain due to 
the change in size of the nicotine molecule. This 
will therefore prevent the release of dopamine 
which is known to cause addiction in a smoker –
thus breaking the vicious cycle of nicotine 
addiction.14 
 
Following vaccination, there  is  an irreversible 
effect on immune system for 6-12 months. This is 
an advantage over the existing cessation therapies 
as it may improve patient compliance to NRT.7  
 
Is nicotine safe? 
Adverse effects caused due to NRT, if any, are 
considered minor and much safer than continuing  
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the use of cigarettes. 
 
Nicotine when delivered from NRT is absorbed 
slowly and reaches lower peak blood levels as 
opposed to the sudden high levels achieved by 
smoking.5 Administration of nicotine using NRT 
also prevents exposure to other toxins found in 
cigarette. However no medication is devoid of 
adverse effects and the use of NRT is no 
exception.7 The adverse effects (other than those 
caused due to nicotine poisoning) are minimal 
and harmless when compared to the deleterious 
effects of smoking. As mentioned above, the 
adverse effects due to NRT which vary with the 
type of delivery system are skin irritation, throat 
irritation, disturbed sleep, nausea, hiccups etc. 
The risk of nicotine poisoning is very rare. The 
acute lethal dose of nicotine is within the range of 
40-60 mg. This can only occur with inappropriate 
use of NRT – use of more than one form of NRT, 
use of dosages higher than recommended or 
continuing smoking while receiving NRT 
therapy.11  
 
CONCLUSION 
Currently there are more myths about NRT and 
only little is known about its efficacy. The 
clinicians and public health centres must spread 
awareness about the effectiveness of NRT. Due to 
lack of information and improper availability of 
NRT, not many people are familiar with this 
therapy. The major belt (living in rural areas of 
India) that is exposed to tobacco products is not 
aware about the ill effects of smoking or the 
benefits of quitting.  
 
To avail utmost advantage of NRT, government 
initiatives should be taken at national level in the 
form of both free of cost availability of NRT to 
people below poverty line and its  awareness at 
dental camps.  
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